107 related articles for article (PubMed ID: 24025975)
1. Severe exacerbation of Crohn's disease during sunitinib treatment.
Boers-Sonderen MJ; Mulder SF; Nagtegaal ID; Jacobs JF; Wanten GJ; Hoentjen F; van Herpen CM
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):234-6. PubMed ID: 24025975
[TBL] [Abstract][Full Text] [Related]
2. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
3. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Diekstra MH; Belaustegui A; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; García-Donas J; Rodríguez-Antona C; Rini BI; Guchelaar HJ
Pharmacogenomics J; 2017 Jan; 17(1):42-46. PubMed ID: 26810136
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
6. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
[No Abstract] [Full Text] [Related]
7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
8. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Khella HWZ; Butz H; Ding Q; Rotondo F; Evans KR; Kupchak P; Dharsee M; Latif A; Pasic MD; Lianidou E; Bjarnason GA; Yousef GM
Mol Ther; 2015 Nov; 23(11):1748-1758. PubMed ID: 26201448
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
10. Fatigue with sunitinib-induced hypothyroidism.
Senior K
Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
[No Abstract] [Full Text] [Related]
11. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
13. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
14. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
[No Abstract] [Full Text] [Related]
15. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
16. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Rodríguez-Reimúndes E; Perazzo F; Vilches AR
Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
Talebi TN; Stefanovic A; Merchan J; Lian E; Silva O
Am J Ther; 2012 Jul; 19(4):e143-5. PubMed ID: 21403468
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib-induced thyrotoxicosis - a not so rare entity.
Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
